Helius Medical Technologies (HSDT)
(Delayed Data from NSDQ)
$4.50 USD
+0.06 (1.35%)
Updated Apr 26, 2024 03:37 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HSDT 4.50 +0.06(1.35%)
Will HSDT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HSDT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HSDT
Wall Street Analysts Predict a 1249.93% Upside in Helius Medical Technologies, Inc. (HSDT): Here's What You Should Know
How Much Upside is Left in Helius Medical Technologies, Inc. (HSDT)? Wall Street Analysts Think 1183.3%
HSDT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Tops Revenue Estimates
Pfizer (PFE) Surpasses Q2 Earnings Estimates
Edwards Lifesciences (EW) Surpasses Q2 Earnings and Revenue Estimates
Other News for HSDT
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
Helius Medical expands stroke clinical program with Shepherd Center
Helius Medical files to sell Class A common stock, warrants
Helius Medical files to sell Class A common stock, warrants, no amount given
12 Health Care Stocks Moving In Friday's Pre-Market Session